Cost Of Reviewing Drugs With AI Is ‘Prohibitive’ For US FDA

A public-private partnership or other solution may be needed for the FDA to handle the costs of reviewing the growing number of drug applications with AI and machine learning components, CDER Director Patrizia Cavazzoni said.